Background: Treatment of metastatic Non–Small Cell lung cancer (mNSCLC) is driven by actionable genomic alterations (AGAs) like EGFR . Liquid biopsies (LBs) are gaining use when tissue is unavailable or insufficient for tumor tissue testing (TT
Search Results
Anne Shah, Jon Apple, Gabriela Burgos, Josh Lankin, Jesse Cohn, Janelle Cambron-Mellott, and Emily Mulvihill
Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck Principal Investigator: Aarti Bhatia, MD, MPH Condition: Recurrent or metastatic squamous cell carcinoma of
Stephen Liu, Pragya Rai, Yu-Han Kao, Diana Chirovsky, and Ana Nunes
included adult pts (≥18 years old) with aNSCLC who initiated 1L therapy from 01-July-2021 to 31-July-2022. Eligibility required confirmed wild-type EGFR and ALK , plus no known ROS 1 rearrangement, for nonsquamous NSCLC, and no documented EGFR
scientific peer-review process and are overseen by the ORP. An NCCN study funded through the grant mechanism is highlighted below. Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in
Amelie Lueders, Annalen Bleckmann, Tim Beißbarth, and Hans-Ulrich Schildhaus
-MET-amplification and colorectal carcinoma (CRC). Systemic antibody therapies targeting EGFR and VEGF provide treatment strategies for patients with advanced disease. Development of resistance to targeted therapy is common and c-met alterations are often found in
by the ORP. This feature highlights an NCCN study funded through the grant mechanism. Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Treatment of Advanced Squamous Cell Cancers of the
by the ORP. This feature highlights an NCCN study funded through the grant mechanism. Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Treatment of Advanced Squamous Cell Cancers of the
Aparna Parikh, Chloe Atreya, W. Michael Korn, and Alan P. Venook
patients with HER2 amplifications and/or HER2-activating mutations may benefit from HER2-directed therapy. HER2 amplifications and activating mutations have also been implicated in resistance to anti–epidermal growth factor receptor (EGFR)–based therapy
NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023
Featured Updates to the NCCN Guidelines
David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm DeCamp, Thomas J. Dilling, Jonathan Dowell, Gregory A. Durm, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo Jr, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Sandip P. Patel, Tejas Patil, Patricio M. Polanco, Gregory J. Riely, Jonathan Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, and Miranda Hughes
. Patients had good performance status (0–1) and did not have known EGFR mutations or ALK fusions. Median event-free survival was 31.6 months (95% CI, 30.2 to not reached) for nivolumab + chemotherapy versus 20.8 months (95% CI, 14.0–26.7) for
Mary E. Charlton, Amanda R. Kahl, Alissa A. Greenbaum, Jordan J. Karlitz, Chi Lin, Charles F. Lynch, and Vivien W. Chen
cured with surgery and neoadjuvant or adjuvant treatments, most are incurable, and treatment focuses on prolonging life and improving quality of life. Targeted agents such as epidermal growth factor receptor (EGFR) inhibitors, including cetuximab, can
